Ryan Jacobs, MD MS

So excited for the 6th Annual William H. Pearce, MD Research Symposium tomorrow, showcasing the research done by our amazing trainees this year, a talk by Edelstone-Bendix Visiting Professor @laparoscopes, and the graduating chiefs residents!

Join us Thursday, June 12 at 9am for the @NMSurgery Research Conference INSIGHT Presentations. We'll hear from Daniel Liesman, MD, Nicole Ontiveros, MD and @John_B_Rode. All moderated by @LaraLopesMD.

Landmark OS data from #CheckMate816 just dropped in @NEJM! 🫁 Neoadjuvant #Nivolumab + chemo in resectable #NSCLC delivers: ✅ 5-yr OS: 65.4% vs 55.0% ✅ HR: 0.72 (p=0.048) ✅ Lung cancer–specific survival HR: 0.65 ✅ OS with pCR: 95.3% ✅ ctDNA clearers: 75%+ OS 📌 No lung…

This is a major story from #ASCO25. Randomized phase 3 trial of time of day of immunotherapy infusion. Randomized to infusion before or after 3pm. Early infusion far superior: PFS 11.3 vs 5.7 HR 0.42, OS HR 0.45! Impactful, pragmatic, not costly. This should be a bigger story.

So you've heard the practice changing exercise CHALLENGE trial! But what did that groundbreaking exercise program actually look like day-to-day? Let's explore the "Structured Exercise Program" based on info from their paper supplement on NEJM #ASCO2025 #ASCO25 1/10

Presented at #ASCO25: A 3-year structured exercise program after adjuvant chemotherapy for colon cancer improved disease-free and overall survival, physical functioning, and fitness, as compared with health education alone. Full CHALLENGE phase 3 trial results:…

As we are heading for the @ASCO-2025, here's a preview of top lung cancer trials, most discussed among oncologists on X, highlighted by @Larvol CLIN. Get the latest #ASCO25 updates: t.ly/7TCD6 #LARVOL #LungCancer #CancerResearch #Oncology #ClinicalTrials…

☑️#ASCO25 Abstract🆙 ☑️#LCSM Oral, LocReg/SCLC 🔥NeoADAURA: Neoadjuvant osimertinib ± chemotherapy (CT) vs CT alone in resectable epidermal growth factor receptor-mutated NSCLC 🎙️ @ChaftJamie 🎯Osi+CT / Osi / PBO+CT: MPR 26%/25%/2%, pCR 4%/9%/0% @OncoAlert @ASCO…

Remarkable results for neoadj chemo-immunotherapy in locally advanced, N2/N3, lung cancer. 75% curative resections w v high pCR. Notably >40% of pts treated had high PD-L1 (unselected would be ~25-30%) but the boundary for lung surgery continues to chase the horizon #LCSM

🔥 Final analysis: CheckMate 577 Adjuvant nivolumab in resected stage II/III EC/GEJC post-CRT & surgery ✅ DFS benefit maintained 21.8 vs 10.8 mo HR 0.76 (95% CI 0.63–0.91) 🧠 DMFS improved 27.3 vs 14.6 mo HR 0.75 (95% CI 0.62–0.90) ⚠️ OS not statistically significant 51.7 vs…

Don't miss the next DOS Research Toolkit Lecture on Thursday, 5/15/25, 9-10 am! We are thrilled to welcome back an alumni panel to discuss early career surgical practice! @NMSurgery

Join us Thursday, May 8 starting at 9am for the @NMSurgery Research Conference Insight Presentations. Presenters will be @SaieeshRao @_paobarrios and @LaraLopesMD. Moderator will be @RaheemBell5

📢Applications are now live for our Michael Zinner HSR Fellowship Program ! ▶️1 yr research fellowship for trainees and junior faculty ▶️Fellow is matched with an SOC faculty member to develop and execute a project ▶️$2K for research-related travel expenses

Join us Thursday, May 17 for the @NMSurgery Research Conference Toolkit Lecture. Presenter will be Joseph Feinglass, PhD. Moderator will be @karenholab . @intmed

Join us for Dr. Joe Feinglass's DOS Research Toolkit Lecture TOMORROW, 4/17/25, at 9 am! @NQUIRES1

Had a great time at the @AmCollSurgeons Residents as Teachers and Leaders Course this past weekend Energizing to be around so many fellow residents interested in improving #SurgEd for ourselves and others #RATL2025

Megan Perez will give tomorrow's DOS Research INSIGHT Talk on her work with @ChadPurnellMD in pediatric plastic surgery! @NMSurgery @shrinershosp

DOS Research Conference is tomorrow at 9 am! Darlene Ratliff will explain how extramural grant proposals are handled by DOS Research Administration. @JessieHo_ and @SaieeshRao will share how they balanced clinical residency with grant planning and preparation! @NMSurgery

Congrats, welcome to the @purplesurg family!

🔥 Much awaited- SANO trial published (Phase 3, non-inferiority trial, 🇳🇱) 309 patients with esophageal cancer with complete response after neoadjuvant chemoradiation (EUS, biopsy, PET) ➡️198 active surveillance, 111 standard surgery. ‼️74% adenocarcinoma 🕰️ Median follow-up…